TruNiagen

Open Life secures funding for longer, healthier lives

Latest articles

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Longeveron completes longevity clinical trial

Longeveron announces successful completion of phase 2b clinical study of Lomecel-B infusion to treat aging frailty. Longeveron Inc, a clinical stage biotechnology company developing cellular...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...
ChromaDex Tru Niagen

Open Life data project secures funding to help UK develop pandemic resilience and promote healthy life extension.

The All Party-Parliamentary Group (APPG) for Longevity has been awarded funding from the Health Foundation to design a framework to harness data in our lives in solutions that will help us live more healthily for longer.

Longevity.Technology: The Open Life Data framework was a recommendation of The Health of the Nation Strategy published a year ago by the APPG to deliver the government goal of five extra years of healthy life expectancy while reducing health inequalities (HLE+5). This news follows last month’s House of Lords report, which argues that the UK Government continues to fail to meet the challenges and realise the opportunities of aging.

The framework will help researchers, policymakers and entrepreneurs work out what non-health data (such as mobility, consumer, financial, environmental) and health data (such as medical records) provide the most insight into helping individuals stay healthy while enhancing overall health resilience at a population health level. This insight will guide the development of ethical, trusted solutions across the private, public, not-for-profit and academic sectors to meet the HLE+5 goal.

 


 

“This is exciting news to further the mission of ‘healthy longevity for all’ and focusing attention on the value of non-health data in health prevention,”

 


 

The framework will identify strategies to achieve pandemic resilience, develop use cases for innovators and entrepreneurs, and inform the value of UK health data assets to feed into UK economic strategy and its global ambition to lead in science and AI.

The principles and methodology of Open Banking will be applied to make health and non-health data useful at scale, taking learnings from the finance model that has successfully opened up innovation to benefit UK consumers.

Adam Steventon, Director of Data Analytics at the Health Foundation says: “We are pleased to be supporting the development of the Open Life Data Framework, which we hope can showcase the value of non-health data in helping achieve better health for everyone. The experience of the pandemic has highlighted the need for responsible and ethical uses of data to be harnessed to help improve health and reduce health inequalities.”

The group, comprising 40 experts, is chaired by Lord James O’Shaughnessy, former Undersecretary of Health and visiting professor at Imperial College. The core team includes Gavin Starks, CEO of Dgen, and co-architect of the Open Banking standard; Professor Iain Buchan, Executive Dean, University of Liverpool; Richard Sloggett, Founder and Programme Director, Future Health Research Centre; and Lord Geoff Filkin and Tina Woods, co-authors of the Health of the Nation Strategy.

Lord O’Shaughnessy says: “The Open Life Data Framework is focussed on extending – and making more equal – the healthy longevity of British citizens across their life course. The UK is already a leader in science and technology and we want to bolster this with individual and population health strategies that will have the greatest short-term and longer-term impact on health and economic resilience post-Covid.”

Tina Woods
Tina Woods, co-author of the Health of the Nation Strategy.

Longevity.Technology reached out to Tina Woods for her reaction. “This is exciting news to further the mission of ‘healthy longevity for all’ and focusing attention on the value of non-health data in health prevention,” she told us. “The longevity community has long talked about the value of open repositories for ageing biomarkers and this comes hot on the heels of the recent Lords Science and Technology Select Committee report calling for more funding in ageing research and using AI to identify accurate biomarkers of ageing for personalised health interventions.”

Damian Green, Chair of the APPG on Longevity, says: “Using data intelligently and ethically to help improve the health of individuals is one of the big post-Covid tasks for the whole health system. I hope this initiative will be a significant step forward in achieving this vital aim.”

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
ChromaDex Tru Niagen

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

Elastrin limbers up for success with Kizoo funding boost

Kizoo provides seed funding for Elastrin Therapeutics to develop ground-breaking new technology capable of reversing tissue and organ calcification. It was announced today that Elastrin,...

Targeting longevity risk management

Vesttoo harnesses the power of AI for data-driven management of longevity risk. Israel-based start-up Vesttoo has developed a set of data-driven risk management solutions for...

AgeX and LyGenesis to negotiate merger agreement

The biotech merger between AgeX and LyGenesis will neaten-up Juvenescence's portfolio. AgeX Therapeutics, a biotech developing therapeutics for human aging and cell regeneration, and LyGenesis,...

$125m secured for xenotransplantation human trials

Series C proceeds will advance two lead xenotransplantation programmes in kidney failure and type 1 diabetes into first-in-human studies. eGenesis, a gene-editing and genome-engineering company...
TruNigen pf